Vident Advisory’s Transmedics TMDX Stock Holding History

Vident Advisory’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,229	Closed	-$222K	–	2039
2026 Q1	$222K	Buy	+2,229	New	+$291K	﹤0.01%	1640

Other funds holding TMDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vident Advisory's TMDX Position: Q2 2026 in Review

Vident Advisory sold out of Transmedics (TMDX) in Q2 2026, closing a stake of 2,229 shares — an estimated $222K sold.

Vident Advisory first reported a position in TMDX in Q1 2026 and held it in 1 quarter. The position peaked at $222K in Q1 2026. 375 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Vident Advisory reported no remaining Transmedics position as of Q2 2026 after selling out during the quarter.
Vident Advisory sold 2,229 Transmedics shares in Q2 2026, an estimated $222K.
Vident Advisory first reported a position in Transmedics in Q1 2026 and held it in 1 quarter.
Vident Advisory's Transmedics position peaked at $222K in Q1 2026.
375 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.